Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

CONCORDBIO is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 0.000000
forwardPE 30.122843
debtToEquity 0.088000
earningsGrowth -0.163000
revenueGrowth 0.137000
grossMargins 0.639150
operatingMargins 0.288850
trailingEps 29.690000
forwardEps 37.795240

Concord Biotech Limited's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
Positive gross and operating margins for CONCORDBIO highlight the company's profitability. These metrics reflect CONCORDBIO's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
Concord Biotech Limited's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for Concord Biotech Limited's financial growth.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

The gradual downward revision of Concord Biotech Limited's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about Concord Biotech Limited's growth potential.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


Concord Biotech Limited has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view Concord Biotech Limited as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.